Similar articles

• Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.

  Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF; FLAME Investigators. Wedzicha JA, et al. N Engl J Med. 2016 Jun 9;374(23):2222-34. doi: 10.1056/NEJMoa1516385. Epub 2016 May 15. N Engl J Med. 2016. PMID: 27181606 Clinical Trial.
• Efficacy and Safety of Indacaterol/Glycopyrronium (IND/GLY) Versus Salmeterol/Fluticasone in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: The Chinese Cohort from the LANTERN Study.

  Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, Patalano F, Banerji D. Zhong N, et al. COPD. 2016 Dec;13(6):686-692. doi: 10.1080/15412555.2016.1182970. Epub 2016 Aug 11. COPD. 2016. PMID: 27715335 Clinical Trial.
• [Dual bronchodilators becomes the first choice combination].

  Einecke D. Einecke D. MMW Fortschr Med. 2016 Jun 9;158(11):18. doi: 10.1007/s15006-016-8350-6. MMW Fortschr Med. 2016. PMID: 27271388 Clinical Trial. German. No abstract available.
• [The combination of indacaterol and glycopyrronium has effects on symptoms, lung function, and rate of exacerbations in COPD patients].

  Ulrik CS. Ulrik CS. Ugeskr Laeger. 2014 Sep 15;176(38):V02140088. Ugeskr Laeger. 2014. PMID: 25294211 Review. Danish.
• Indacaterol/glycopyrronium: a dual bronchodilator for COPD.

  Banerji D, Fogel R, Patalano F. Banerji D, et al. Drug Discov Today. 2018 Jan;23(1):196-203. doi: 10.1016/j.drudis.2017.10.015. Epub 2017 Oct 24. Drug Discov Today. 2018. PMID: 29079130 Review.